Latigo Biotherapeutics files initial beneficial ownership statement for Sanofi
LTGO•Sanofi files Form 3 for Latigo stake
Sanofi filed a Form 3 disclosing 10% ownership in Latigo Biotherapeutics as of Aug. 6, 2026.
The filing reported:
- Indirect beneficial ownership of 494,800 shares underlying Series B Preferred Stock.
- Indirect beneficial ownership of 177,978 shares underlying a Convertible Promissory Note.
